文献速递银屑病与炎症性皮肤病

COVID-19大流行期间银屑病患者对系统性免疫调节治疗的不依从:全球横断面调查结果

Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey.
PubMed 文献 · Br J Dermatol · 2023-01-01

该全球在线自报调查(PsoProtectMe)在COVID-19大流行第一年纳入77个国家3980名银屑病患者,其中1611人(40.5%)使用系统性免疫调节治疗,408人(25.3%)报告不依从,最常见原因为担心免疫力。焦虑筛查阳性与不依从在未调整模型中相关(OR 1.37,95%CI 1.07-1.76),但调整混杂因素后关联未达统计学显著(OR 1.20,95%CI 0.92-1.56)。

要点

  • 大流行期间25.3%使用系统性免疫调节治疗的银屑病患者报告不依从,主要原因为担心免疫力。
  • 未调整模型中焦虑筛查阳性与不依从相关(OR 1.37,95%CI 1.07-1.76),调整后未达统计学显著。
  • 抑郁筛查阳性与不依从在未调整(OR 1.22,95%CI 0.94-1.57)和调整模型(OR 1.14,95%CI 0.87-1.49)中均无强关联。

核心结论

  • 大流行期间银屑病患者对系统性免疫调节治疗存在显著不依从,调整混杂因素后心理健康的关联减弱。
  • 未来需在更大规模人群中进一步探索大流行特异性的治疗不依从驱动因素。
  • 向银屑病患者清晰传达基于人群研究的关于免疫调节治疗相关COVID-19不良风险的可信发现,对优化依从性和疾病结局至关重要。

研究设计与样本

  • 全球在线自报调查(PsoProtectMe),包含经验证的焦虑和抑郁筛查工具,在大流行第一年完成。
  • 共纳入来自77个国家的3980名参与者,其中1611名(40.5%)被处方系统性免疫调节治疗。
  • 采用二项逻辑回归评估焦虑或抑郁与系统性免疫调节治疗不依从的关联,并调整年龄、性别、 ethnicity、合并症和居住国家等潜在混杂因素。

主要发现

  • 1611名被处方系统性免疫调节治疗者中,408名(25.3%)报告大流行期间不依从,最常见原因为担心免疫力。
  • 未调整模型中,焦虑筛查阳性与系统性免疫调节治疗不依从相关(OR 1.37,95%CI 1.07-1.76)。
  • 焦虑与靶向治疗不依从相关(OR 1.41,95%CI 1.01-1.96),但与标准系统性治疗不依从无显著关联(OR 1.16,95%CI 0.81-1.67)。
  • 调整模型中,焦虑与总体系统性免疫调节治疗不依从(OR 1.20,95%CI 0.92-1.56)或靶向治疗不依从(OR 1.33,95%CI 0.94-1.89)的关联方向不变但未达统计学显著。
  • 抑郁筛查阳性与系统性免疫调节治疗不依从在未调整模型(OR 1.22,95%CI 0.94-1.57)和调整模型(OR 1.14,95%CI 0.87-1.49)中均无强关联。

临床怎么用

  • 作者认为,应向银屑病患者清晰传达基于人群研究的关于免疫调节治疗相关COVID-19不良风险的可信发现,以优化依从性和疾病结局。

局限性

  • 未来需在更大规模人群中进一步研究大流行特异性的治疗不依从驱动因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nonadherence to immune-modifying therapy is a complex behaviour which, before the COVID-19 pandemic, was shown to be associated with mental health disorders in people with immune-mediated diseases. The COVID-19 pandemic has led to a rise in the global prevalence of anxiety and depression, and limited data exist on the association between mental health and nonadherence to immune-modifying therapy during the pandemic. OBJECTIVES: To assess the extent of and reasons underlying nonadherence to systemic immune-modifying therapy during the COVID-19 pandemic in individuals with psoriasis, and the association between mental health and nonadherence. METHODS: Online self-report surveys (PsoProtectMe), including validated screens for anxiety and depression, were completed globally during the first year of the pandemic. We assessed the association between anxiety or depression and nonadherence to systemic immune-modifying therapy using binomial logistic regression, adjusting for potential cofounders (age, sex, ethnicity, comorbidity) and country of residence. RESULTS: Of 3980 participants from 77 countries, 1611 (40.5%) were prescribed a systemic immune-modifying therapy. Of these, 408 (25.3%) reported nonadherence during the pandemic, most commonly due to concerns about their immunity. In the unadjusted model, a positive anxiety screen was associated with nonadherence to systemic immune-modifying therapy [odds ratio (OR) 1.37, 95% confidence interval (CI) 1.07-1.76]. Specifically, anxiety was associated with nonadherence to targeted therapy (OR 1.41, 95% CI 1.01-1.96) but not standard systemic therapy (OR 1.16, 95% CI 0.81-1.67). In the adjusted model, although the directions of the effects remained, anxiety was not significantly associated with nonadherence to overall systemic (OR 1.20, 95% CI 0.92-1.56) or targeted (OR 1.33, 95% CI 0.94-1.89) immune-modifying therapy. A positive depression screen was not strongly associated with nonadherence to systemic immune-modifying therapy in the unadjusted (OR 1.22, 95% CI 0.94-1.57) or adjusted models (OR 1.14, 95% CI 0.87-1.49). CONCLUSIONS: These data indicate substantial nonadherence to immune-modifying therapy in people with psoriasis during the pandemic, with attenuation of the association with mental health after adjusting for confounders. Future research in larger populations should further explore pandemic-specific drivers of treatment nonadherence. Clear communication of the reassuring findings from population-based research regarding immune-modifying therapy-associated adverse COVID-19 risks to people with psoriasis is essential, to optimize adherence and disease outcomes.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Quirke-McFarlane S, Weinman J, Cook ES, et al. Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey. Br J Dermatol. 2023. PMID: 36763806. doi:10.1093/bjd/ljac144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。